The Down Under medical sector is excited with the arrival of retatrutide, a groundbreaking dual GIP and GLP-1 medication showing remarkable results in early trials for treating obesity. This therapy offers https://veriea.com/2026/06/10/retatrutide-australia-the-next-generation-in-weight-loss/